These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20024492)

  • 1. What is the appropriate approach to prevention of thromboembolism in heart failure?
    Freudenberger RS; Schumaecker MM; Homma S
    Thromb Haemost; 2010 Mar; 103(3):489-95. PubMed ID: 20024492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Heart failure and arrhythmia: modalities and indications of prevention of thromboembolism].
    Prati PL; Piazza V
    Cardiologia; 1994 Dec; 39(12 Suppl 1):353-6. PubMed ID: 7634296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do we know about anticoagulation in patients with heart failure?
    Ahnert AM; Freudenberger RS
    Curr Opin Cardiol; 2008 May; 23(3):228-32. PubMed ID: 18382211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboembolism and antithrombotic therapy in congestive heart failure.
    Dunkman WB
    J Cardiovasc Risk; 1995 Apr; 2(2):107-17. PubMed ID: 7606647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [For which patients with cardiac decompensation is prevention of thromboembolism advisable?].
    G Ital Cardiol; 1994 Oct; 24(10):1341-6. PubMed ID: 7835568
    [No Abstract]   [Full Text] [Related]  

  • 6. Anticoagulation for heart failure: selecting the best therapy.
    Kohsaka S; Homma S
    Expert Rev Cardiovasc Ther; 2009 Oct; 7(10):1209-17. PubMed ID: 19814664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk?
    Katz SD
    J Cardiovasc Risk; 1995 Apr; 2(2):97-102. PubMed ID: 7606657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice.
    Siliste RN; Antohi EL; Pepoyan S; Nakou E; Vardas P
    Eur J Heart Fail; 2018 Jun; 20(6):978-988. PubMed ID: 29504188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation in patients with heart failure.
    Bhatia RS; Ouzounian M; Tu JV; Liu PP; Lee DS
    Cardiovasc Hematol Agents Med Chem; 2009 Jul; 7(3):193-7. PubMed ID: 19689257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Dunkman WB; Johnson GR; Carson PE; Bhat G; Farrell L; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI94-101. PubMed ID: 8500246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticoagulant therapy in patients with dilated cardiomyopathy].
    Gensini GF; Rostagno C
    Ann Ital Med Int; 1998; 13(4):227-32. PubMed ID: 10349204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of venous thromboembolism among hospitalized medical patients.
    Goldhaber SZ; Turpie AG
    Circulation; 2005 Jan; 111(1):e1-3. PubMed ID: 15630031
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood coagulation in patients with chronic heart failure: evidence for hypercoagulable state and potential for pharmacological intervention.
    De Lorenzo F; Saba N; Kakkar VV
    Drugs; 2003; 63(6):565-76. PubMed ID: 12656654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
    Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antithrombotic prophylaxis in patients with ventricular dysfunction: critical review of the literature and new perspectives].
    Scardi S; Mazzone C
    Ital Heart J Suppl; 2003 Mar; 4(3):201-9. PubMed ID: 12784754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticoagulation in chronic heart failure and left ventricular dysfunction].
    Wichter T; Breithardt G
    Dtsch Med Wochenschr; 2002 Oct; 127(41):2145-8. PubMed ID: 12397561
    [No Abstract]   [Full Text] [Related]  

  • 18. [Oral anticoagulation for prevention of thromboembolism in non-rheumatic atrial fibrillation: indications, effectiveness and risk].
    Kottkamp H; Willems S; Hindricks G; Chen X; Haverkamp W; Hasfeld M; Borggrefe M; Breithardt G
    Z Kardiol; 1993 Nov; 82(11):667-73. PubMed ID: 8291287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
    Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction.
    Baker DW; Wright RF
    JAMA; 1994 Nov 23-30; 272(20):1614-8. PubMed ID: 7966873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.